GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Change In Payables And Accrued Expense

Noile-Immune Biotech (TSE:4893) Change In Payables And Accrued Expense : 円0.0 Mil (TTM As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Noile-Immune Biotech Change In Payables And Accrued Expense?

Noile-Immune Biotech's Change In Payables And Accrued Expense for the quarter that ended in Mar. 2024 was 円0.0 Mil. It means Noile-Immune Biotech's Accounts Payable & Accrued Expense stayed the same from Dec. 2023 to Mar. 2024 .

Noile-Immune Biotech's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2023 was 円0.0 Mil. It means Noile-Immune Biotech's Accounts Payable & Accrued Expense stayed the same from Dec. 2022 to Dec. 2023 .

Noile-Immune Biotech Change In Payables And Accrued Expense Historical Data

The historical data trend for Noile-Immune Biotech's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Noile-Immune Biotech Change In Payables And Accrued Expense Chart

Noile-Immune Biotech Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Change In Payables And Accrued Expense
- - - -

Noile-Immune Biotech Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Change In Payables And Accrued Expense Get a 7-Day Free Trial Premium Member Only - - - - -

Noile-Immune Biotech Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Noile-Immune Biotech Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Noile-Immune Biotech's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Noile-Immune Biotech (TSE:4893) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Noile-Immune Biotech Inc (TSE:4893) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
TSE:4575 TSE:4563 TSE:4978 TSE:4579 TSE:7774 TSE:2183 TSE:7096 TSE:4894 TSE:4571 TSE:4593 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
2-12-10 Shiba-Daimon, Minato-ku, Tokyo, JPN, 105-0012
Website
https://www.noile-immune.com
Noile-Immune Biotech Inc is engaged in the development of novel cancer immunotherapy including CAR-T cell therapy.

Noile-Immune Biotech (TSE:4893) Headlines

No Headlines